Comparative Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors vs Sulfonylureas in Patients With Type 2 Diabetes

Study (n=128,293 on metformin) found use of SGLT2 inhibitors linked to reduced risk of all-cause mortality compared with sulfonylureas (HR, 0.81; 95% CI, 0.75-0.87), regardless of CVD status, estimated glomerular filtration rate category, and albuminuria status

Source:

JAMA Internal Medicine